Clinical assessment reports visual and anatomic responses to intravitreal faricimab in resistant neovascular macular degeneration, suggesting salvage pathways for anti-VEGF therapy.
To determine the efficacy of switching to intravitreal (IVT) faricimab in patients with treatment-resistant neovascular age-related macular degeneration (nAMD) and determine the rates of reversion to original antivascular endothelial growth factor (anti-VEGF) therapy.
No takes yet. Share an insight, caveat, or question.
Khodor et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: